# Bayer: Observational study completed, 604 enrolled (Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Bayer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions |
| NCT ID | NCT06632483 |
| Phase | Observational |
| Status | completed |
| Conditions | Chronic Heart Failure With Reduced Ejection Fraction; Worsening Chronic Heart Failure |
| Intervention types | drug |
| Target enrollment | 604 |
| Site countries | India |
| Posted | 2024-10-09 |
| Planned start | 2025-09-08 |
| Event | Completed |
| Event date | 2026-09-30 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- 604 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06632483). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.